UNSPSC 51386202: Olsalazine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ULS5I8J03O, chemically known as 1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine but generally known as olsalazine, which bears US NIH Compound Identifier 4205. European Medicines Agency schedules Olsalazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09436MIG.

UNSPSC 51386202 Olsalazine, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally covers olsalazine, a specific anti-inflammatory pharmaceutical used in ulcerative colitis treatment, yet the three recent opportunities posted under this code solicit naloxone (an opioid antagonist), safe drug deactivation systems, multi-source generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — none of which are olsalazine or closely related to it. The tagging appears to reflect a broader pharmaceutical procurement classification at the state and local level rather than molecule-specific sourcing. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating states including Oregon). The mix spans public health emergency response, pharmacy benefit program management, and bulk pharmaceutical supply.

Recent activity concentrates in Florida, Texas, and Minnesota, with cooperative purchasing vehicles extending reach across multiple jurisdictions. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, response due July 26, 2023. Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a direct-to-manufacturer prescription program without a formal response deadline or budget range. Minnesota's cooperative purchasing office issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products from participating wholesalers, with proposals due March 26, 2026, and July 1, 2026 contract effective date. Vendor qualifications typically require FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, E-Verify authorization, and substantial insurance coverage. Given the mismatch between code definition and actual procurement scope, olsalazine-specific activity under this code does not appear in current state and local solicitations.